Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

被引：0
|
作者：
Florence Lerebours
Marina Pulido
Emmanuelle Fourme
Marc Debled
Véronique Becette
Hervé Bonnefoi
Sofia Rivera
Gaetan MacGrogan
Marie-Ange Mouret-Reynier
Christine Tunon de Lara
Jean-Yves Pierga
Christel Breton-Callu
Laurence Venat-Bouvet
Simone Mathoulin-Pélissier
Thibault de la Motte rouge
Florence Dalenc
Brigitte Sigal
Thomas Bachelot
Jérôme Lemonnier
Nathalie Quenel-Tueux
机构：
[1] Institut Curie,Department of Radiation Oncology
[2] Clinical and Epidemiological Research Unit,undefined
[3] Institut Bergonié,undefined
[4] INSERM CIC 14.01,undefined
[5] Institut Bergonié,undefined
[6] Institut Curie,undefined
[7] Gustave Roussy Cancer Campus,undefined
[8] Centre Jean Perrin,undefined
[9] CHU,undefined
[10] Centre Eugène Marquis,undefined
[11] Institut Claudius Regaud-IUCT Oncopole,undefined
[12] Centre Léon Bérard,undefined
[13] R&D UNICANCER,undefined
[14] UCBG,undefined
来源：
British Journal of Cancer | 2020年 / 122卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：759 / 765
页数：6
相关论文
共 50 条
  • [31] A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2- advanced breast cancer
    Jerusalem, Guy
    Bachelot, Thomas
    Barrios, Carlos
    Neven, Patrick
    Di Leo, Angelo
    Janni, Wolfgang
    de Boer, Richard
    CANCER TREATMENT REVIEWS, 2015, 41 (02) : 94 - 104
  • [32] Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
    Guiu, S.
    Reynier, M. A. Mouret
    Toure, M.
    Coudert, B.
    JOURNAL OF ONCOLOGY, 2013, 2013
  • [33] Abemaciclib plus fulvestrant in participants with HR+/HER2-advanced breast cancer: A pooled analysis of the endocrine therapy naive (EN) participants in MONARCH 2
    Luis-Gonzalez Trujillo, J.
    Escobar Gomez, M.
    Sohn, J. H.
    Im, Y-H.
    Wang, H-C.
    Cussac, A. Llombart
    Zhang, W.
    Haddad, N.
    Wasserstrom, H.
    van Hal, G.
    Sledge, G. W., Jr.
    ANNALS OF ONCOLOGY, 2021, 32 : S464 - S465
  • [34] Gain of HER2 Amplification in Patients with HR+/HER2-and Triple Negative Early Breast Cancer Treated with Neoadjuvant Chemotherapy
    Ferraro, Emanuela
    Minmin, Sonya Chew
    Safonov, Anton
    Barrio, Andrea V.
    Modi, Shanu
    Seidman, Andrew D.
    Wen, Hanna Y.
    Brogi, Edi
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2023, 83 (05)
  • [35] Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2-advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies
    Rugo, H. S.
    Turner, N. C.
    Finn, R. S.
    Joy, A. A.
    Verma, S.
    Harbeck, N.
    Moulder, S.
    Masuda, N.
    Im, Y-H
    Zhang, K.
    Kim, S.
    Sun, W.
    Schnell, P.
    Huang-Bartlett, C.
    Slamon, D.
    CANCER RESEARCH, 2017, 77
  • [36] Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+advanced breast cancer patients
    Liang, Yuehua
    Liu, Xiaoran
    Yun, Zehui
    Li, Kun
    Li, Huiping
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [37] Toxicity of abemaciclib plus endocrine therapy for HR+HER2-advanced breast cancer in Caucasian patients - pooled analysis from MONARCH 2 and 3 trials
    Kisro, J.
    Ettl, J.
    Korfel, A.
    Herbertz, S.
    Stoffregen, C.
    Huober, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 162 - 162
  • [38] Retrospective analysis of first-line progression free survival compared endocrine therapy and chemotherapy inpatients with HR+/HER2-metastatic breast cancer
    Xu, Junnnan
    Sun, Tao
    CANCER RESEARCH, 2020, 80 (04)
  • [39] Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
    Lu, Yen-Shen
    Im, Seock-Ah
    Colleoni, Marco
    Franke, Fabio
    Bardia, Aditya
    Cardoso, Fatima
    Harbeck, Nadia
    Hurvitz, Sara
    Chow, Louis
    Sohn, Joohyuk
    Lee, Keun Seok
    Campos-Gomez, Saul
    Vazquez, Rafael Villanueva
    Jung, Kyung Hae
    Babu, K. Govind
    Wheatley-Price, Paul
    De Laurentiis, Michelino
    Im, Young-Hyuck
    Kuemmel, Sherko
    El-Saghir, Nagi
    O'Regan, Ruth
    Gasch, Claudia
    Solovieff, Nadia
    Wang, Craig
    Wang, Yongyu
    Chakravartty, Arunava
    Ji, Yan
    Tripathy, Debu
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 851 - 859
  • [40] Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer
    Fasching, P. A.
    Fernandez Abad, M.
    Garcia-Saenz, J. A.
    Schneeweiss, A.
    Guarneri, V.
    Colleoni, M.
    Petru, E.
    Costigan, T. M.
    Caldwell, C. W.
    Barriga, S.
    Hurvitz, S.
    Slamon, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 225 - +
12345